F. Hoffmann-La Roche Ltd.
Product Development Neuroscience
Szofia S Bullain, MD Senior Medical Director, Product Development Neuroscience, Roche Dr. Bullain is a board-certified Geriatric Neurologist and Alzheimer’s disease specialist who serves as a Senior Medical Director for Neuroscience Product Development at Roche, in Basel Switzerland. Prior to joining Roche in 2017, Dr. Bullain was a full-time faculty member in the Department of Neurology at the University of California, Irvine (UCI) School of Medicine, working as an Assistant Professor of Neurology. Dr. Bullain attained her Medical Doctorate at Semmelweis University, in her native city Budapest, Hungary. After graduating from Medical School, Dr. Bullain moved to the United States where she completed more than 12 years of training in neurology and neuroscience at Harvard Medical School, SUNY Buffalo and UCI.

Presenter of 4 Presentations

From clinical trials to reality

Session Type
PRE CONFERENCE SYMPOSIUM
Date
Tue, 15.03.2022
Session Time
12:30 PM - 05:30 PM
Room
ONSITE: 112
Lecture Time
12:40 PM - 01:40 PM

SKYLINE STUDY DESIGN: EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT-RISK FOR OR AT THE EARLIEST STAGES OF ALZHEIMER’S DISEASE

Session Type
SYMPOSIUM
Date
Fri, 18.03.2022
Session Time
02:45 PM - 04:45 PM
Room
ONSITE: 112
Lecture Time
04:00 PM - 04:15 PM

Abstract

Aims

The anti-amyloid beta (Aβ) monoclonal antibody gantenerumab is in late-phase clinical development for early (prodromal-to-mild) Alzheimer’s disease (AD). Here we describe an upcoming Phase III multicentre, randomised, parallel-group, double-blind, placebo-controlled secondary prevention study (SKYLINE), evaluating the efficacy and safety of subcutaneous gantenerumab in participants at risk for or at the earliest stages of AD.

Methods

SKYLINE will enrol ~1,200 cognitively unimpaired participants (Clinical Dementia Rating Global Score=0 and Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index ≥80), aged 60–80, with confirmed Aβ pathology (cerebrospinal fluid [CSF] or positron emission tomography [PET]). Screening includes an optional exploratory blood-based biomarker (BBBM) pre-screening to predict Aβ positivity. Participants will be randomised 1:1 to 211 weeks subcutaneous gantenerumab (titrated to 1,020 mg monthly dosage) or placebo treatment administered weekly or every other week. Any participant confirmed as progressing to mild cognitive impairment or AD dementia during the study will undergo a blinded post-progression dose escalation, during which participants on placebo switch to gantenerumab. All parties will remain blinded to the assigned treatment at randomization.

Results

The primary endpoint is change from baseline to Year 4 in the Preclinical Alzheimer’s Cognitive Composite-5 score. Secondary and exploratory objectives include further efficacy assessments (e.g., clinical progression), safety (e.g., adverse events, amyloid-related imaging abnormalities), pharmacodynamic biomarkers (Aβ/Tau PET, CSF, BBBM), pharmacokinetics, and identification of additional biomarkers.

Conclusions

SKYLINE will be the first secondary prevention study of subcutaneous gantenerumab in cognitively unimpaired participants at risk for or at the earliest stages of AD.

Hide